NHCS contract signals Asia-Pacific momentum for Hydrix Medical
Hydrix Limited (ASX: HYD), through its wholly owned subsidiary Hydrix Medical Pty Ltd, has secured a multi-year contract with the National Heart Centre Singapore (NHCS) for deployment of the Implicity™ cloud-based remote cardiac monitoring platform. The contract carries an estimated value of approximately A$0.625 million over three years, generating approximately A$0.21 million in annual recurring revenue (ARR), subject to patient volumes monitored under the platform.
Implementation is expected to commence shortly, with revenue flowing to Hydrix upon implementation. NHCS is Singapore’s national and regional referral centre for cardiovascular diseases, a member of SingHealth (Singapore’s largest healthcare group), and one of Asia’s most respected cardiac institutions.
When big ASX news breaks, our subscribers know first
What the Implicity platform does — and why it matters
Cardiac Implantable Electronic Devices (CIEDs) are surgically implanted devices used to manage serious heart conditions. They include pacemakers (which regulate heart rhythm), implantable cardioverter defibrillators (ICDs, which deliver shocks to correct dangerous arrhythmias), and cardiac resynchronisation therapy devices (which coordinate the pumping action of the heart). Remote monitoring of these devices allows clinicians to track patient data continuously without requiring in-person visits, enabling earlier intervention when issues arise.
The Implicity platform addresses a key operational challenge in CIED management: data fragmentation across multiple device manufacturers. Its core capabilities include:
- Aggregation and standardisation of data from all major CIED manufacturers into a single interface
- Normalisation of device data to support consistent clinical interpretation
- AI-based analytics designed to support earlier intervention
- Multi-manufacturer compatibility, reducing the need for separate monitoring systems
For investors, the platform’s cloud-based architecture is significant. Revenue is subject to patient volumes monitored, creating a scalable, recurring revenue model that is inherently linked to clinical adoption.
Contract details and commercial structure
Key terms at a glance
| Detail | Value |
|---|---|
| Contract party | National Heart Centre Singapore (NHCS) |
| Platform | Implicity™ cloud-based remote cardiac monitoring platform |
| Contract duration | Multi-year (three years) |
| Estimated total contract value | Approximately A$0.625 million (subject to patient volumes) |
| Annual recurring revenue (ARR) | Approximately A$0.21 million per annum |
| Revenue trigger | Revenue flows to Hydrix upon implementation |
| Deployment model | Cloud deployment delivered jointly by Implicity and Hydrix Medical |
It is important to note that pricing and patient numbers are commercial-in-confidence. The A$0.625 million figure is an estimate, subject to patient volumes, and should not be read as a fixed or guaranteed sum.
Reference site strategy
Beyond the direct contract value, NHCS has been explicitly identified as a “key reference customer” to support further expansion across Singapore, Australia, and the broader Asia-Pacific region. For prospective institutional customers evaluating the Implicity platform, a deployment at a nationally recognised cardiac centre of NHCS’s standing carries meaningful credibility. This reference site status is likely to reduce friction in future sales conversations and accelerate the pipeline, making the commercial value of this win larger than the A$0.625 million contract figure alone.
Vickie Edwards, Director Sales & Operations, Hydrix Medical
“Securing National Heart Centre Singapore as a customer is a significant commercial milestone for Hydrix Medical and an important validation of our Asia-Pacific growth strategy…”
What this means for the Hydrix investment case
Hydrix Limited is an Australian technology company operating across medical technology, defence, industrial, and mining. This NHCS contract advances the medical technology arm’s recurring revenue base, adding a visible ARR contribution to Hydrix Medical’s revenue line.
The NHCS win extends a pattern of cardiac-focused commercial momentum for Hydrix Medical, building on the SynCardia artificial heart contract secured earlier in 2026, which formed part of a $3.7 million contract package representing approximately 85% of the company’s market capitalisation at the time.
Investors monitoring this development should watch for the following:
- Implementation commencement and the timing of first revenue recognition under the contract
- Patient volume ramp as NHCS adopts the platform across its CIED patient population, which will directly determine realised ARR
- Follow-on opportunities in Singapore and the broader Asia-Pacific region, enabled by NHCS’s status as a named reference site
- Complementary opportunities in Australia, also identified by management as a target market for further expansion
Arnaud Rosier, PhD, Chief Executive Officer, Implicity
“…This deployment supports our international growth strategy and reinforces the value that next-generation remote monitoring and AI-enabled cardiac care can deliver to leading healthcare institutions.”
With implementation expected to commence shortly, the approximately A$0.21 million in anticipated annual recurring revenue provides a visible, volume-linked contribution to Hydrix Medical’s revenue profile. The strategic significance of establishing a reference site at one of Asia’s leading cardiac institutions positions the subsidiary for broader regional growth beyond this initial agreement.
For investors exploring the full scope of Hydrix’s AI and engineering positioning across the medtech sector, our detailed coverage of the Quantanosis AI-robotic stroke platform engagement examines how the company is building capabilities at the intersection of robotics, artificial intelligence, and therapeutic ultrasound delivery, with implications for its longer-term medtech pipeline.
Don’t Miss the Next Healthcare Breakout on the ASX
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who never miss a market-moving announcement. Click the “Free Alerts” button at Big News Blast to stay ahead the moment news breaks.